Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

The purpose of this study is to investigate the role of the pulmonary vasculature in the development and progression of chronic obstructive pulmonary disease (COPD). To accomplish this, an inhaled prostacyclin (iloprost) will be given to patients with COPD and changes in oxidative stress and lung volumes during exercise will be measured.

Key facts

Study ID

NCT01941225

Run by

Louisiana State University Health Sciences Center in New Orleans

People needed

24

Starts

2013-09-01

Expected to finish

2016-11-01

Last updated by the study team

2016-12-16

Who can join

Age: 40 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 40 years old or older
• Physician diagnosis of chronic obstructive pulmonary disease
• 10 or more pack-year smoking history
• FEV1/FVC <0.70
• FEV1 35-80% of predicted

You may not qualify if…

• Acute exacerbation of COPD within the last 30 days
• Pregnant or breast-feeding
• Contraindications to cardiopulmonary exercise testing
• Known intolerance or allergy to iloprost
• On oral corticosteroids (may be included if off for 7 days prior to testing)
• Supplemental oxygen need
• Known inflammatory disease other than COPD
• Active solid organ/hematologic malignancy

Where it is running

• LSU Health Sciences Center — New Orleans, Louisiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.